Trial record 4 of 14 for:
Merck | cutaneous squamous carcinoma
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06295809 |
|
Recruitment Status :
Recruiting
First Posted : March 6, 2024
Last Update Posted : May 13, 2024
|
Sponsor:
Merck Sharp & Dohme LLC
Collaborator:
Moderna TX
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2029 |
| Estimated Study Completion Date : | May 6, 2033 |